ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2022

The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.

Chung-Pu Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.